Abstract
Global rates of pulmonary tuberculosis (TB) continue to increase. Moreover, resistance of the causative organism Mycobacterium tuberculosis to the two most effective anti-TB medications continue to rise. Now, multi-drug resistant TB (MDR-TB) has progressed to extensively drug resistant TB (XDR-TB) - a M. tuberculosis organism that is resistant to the most effective second line drugs available for the treatment of TB. This review provides detailed, significant evidence that supports the use of an old neuroleptic compound, thioridazine (TZ), for the management of MDR-TB and XDR-TB infections and which has been shown to inhibit efflux pumps of bacteria. The argument has been previously presented but no one seems to be listening - and the disease continues unabated when there is a very good probability that the suggested drug will prove to be effective. When the prognosis is poor, available therapy predictably ineffective and death is inevitable, compassionate therapy with TZ should be contemplated. The risks are small and the rewards great.
Keywords: Therapy of MDR-TB, XDR-TB, Mycobacterium tuberculosis, thioridazine, efflux pumps
Current Drug Targets
Title: Promising Therapy of XDR-TB/MDR-TB with Thioridazine an Inhibitor of Bacterial Efflux Pumps
Volume: 9 Issue: 9
Author(s): L. Amaral, M. Martins, M. Viveiros, J. Molnar and J. E. Kristiansen
Affiliation:
Keywords: Therapy of MDR-TB, XDR-TB, Mycobacterium tuberculosis, thioridazine, efflux pumps
Abstract: Global rates of pulmonary tuberculosis (TB) continue to increase. Moreover, resistance of the causative organism Mycobacterium tuberculosis to the two most effective anti-TB medications continue to rise. Now, multi-drug resistant TB (MDR-TB) has progressed to extensively drug resistant TB (XDR-TB) - a M. tuberculosis organism that is resistant to the most effective second line drugs available for the treatment of TB. This review provides detailed, significant evidence that supports the use of an old neuroleptic compound, thioridazine (TZ), for the management of MDR-TB and XDR-TB infections and which has been shown to inhibit efflux pumps of bacteria. The argument has been previously presented but no one seems to be listening - and the disease continues unabated when there is a very good probability that the suggested drug will prove to be effective. When the prognosis is poor, available therapy predictably ineffective and death is inevitable, compassionate therapy with TZ should be contemplated. The risks are small and the rewards great.
Export Options
About this article
Cite this article as:
Amaral L., Martins M., Viveiros M., Molnar J. and Kristiansen E. J., Promising Therapy of XDR-TB/MDR-TB with Thioridazine an Inhibitor of Bacterial Efflux Pumps, Current Drug Targets 2008; 9 (9) . https://dx.doi.org/10.2174/138945008785747798
DOI https://dx.doi.org/10.2174/138945008785747798 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: New Developments in the Search for Agents to Treat Tuberculosis)
Current Topics in Medicinal Chemistry Pertussis Vaccines: State-of-the-Art and Future Trends
Current Topics in Medicinal Chemistry Chemistry and Applications of 4-Hydroxyquinolin-2-one and Quinoline-2,4-dionebased Compounds
Current Organic Chemistry Editorial (Thematic Issue: The Lab-on-a-protein Concept Protein as Powerful Nanometric Laboratory for Chemical Sciences)
Current Organic Chemistry Coffee and Depression: A Short Review of Literature
Current Pharmaceutical Design Immune Monitoring to Predict the Development of Infections After Immunosuppression for Solid Organ Transplantation and Autoimmune Diseases
Current Drug Safety The Physiology of Nitric Oxide: Control and Consequences
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Alcohol Abuse, Immunosuppression, and Pulmonary Infection
Current Drug Abuse Reviews Cofactor Biosynthetic Pathways in Mycobacterium tuberculosis as Potential Drug Targets
Current Respiratory Medicine Reviews Design of Fucoidan Functionalized - Iron Oxide Nanoparticles for Biomedical Applications
Current Drug Delivery Inhibition of the Archaeal β-Class (Cab) and γ-Class (Cam) Carbonic Anhydrases
Current Topics in Medicinal Chemistry Brevifoliol and its Analogs: A New Class of Anti-tubercular Agents
Current Topics in Medicinal Chemistry Study of Stability of New Mutual Prodrugs with Antimycobacterial Activity
Current Organic Chemistry The Significant Role of Nutraceutical Compounds in Ulcerative Colitis Treatment
Current Medicinal Chemistry Understanding the Structure, Activity and Inhibition of Chorismate Synthase from Mycobacterium tuberculosis
Current Medicinal Chemistry Updated Acute Community-Acquired Pneumonia in Adults: Guidelines for Initial Antimicrobial Therapy Based on Local Evidence from the South American Working Group (Consensur II)
Current Respiratory Medicine Reviews The β-Carbonic Anhydrases from Mycobacterium tuberculosis as Drug Targets
Current Pharmaceutical Design The Interplay of Disease Modifying Anti Rheumatic Drugs and Tuberculin Skin Test
Current Reviews in Clinical and Experimental Pharmacology Genus Euonymus: Chemical and Pharmacological Perception
Mini-Reviews in Organic Chemistry PeMtb: A Database of MHC Antigenic Peptide of Mycobacterium tuberculosis
Current Pharmaceutical Biotechnology